Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ali K Naji"'
Autor:
Michael J. McCarthy, Cynthia V. Pagba, Priyanka Prakash, Ali K. Naji, Dharini van der Hoeven, Hong Liang, Amit K. Gupta, Yong Zhou, Kwang-Jin Cho, John F. Hancock, Alemayehu A. Gorfe
Publikováno v:
ACS Omega, Vol 4, Iss 2, Pp 2921-2930 (2019)
Externí odkaz:
https://doaj.org/article/a2f4b1b42550469ea496ea68f35e14d4
Autor:
Cynthia V. Pagba, Amit K. Gupta, Ali K. Naji, Dharini van der Hoeven, Kelly Churion, Xiaowen Liang, Jacob Jakubec, Magnus Hook, Yan Zuo, Marisela Martinez de Kraatz, Jeffrey A. Frost, Alemayehu A. Gorfe
Publikováno v:
ACS Bio & Med Chem Au. 2:617-626
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecb8240026e1f84295253a0081e46413
https://doi.org/10.1021/acsbiomedchemau.2c00045
https://doi.org/10.1021/acsbiomedchemau.2c00045
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 34
Background: Vascular endothelial growth factor (VEGF) is a signal protein that induces vasculogenesis and angiogenesis, which are important to atheroma progression. Bevacizumab is a humanized monoclonal antibody specific for VEGF that causes regressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfa0e0e339f67b6bc342fb5fc3a9c625
https://doi.org/10.1161/atvb.34.suppl_1.263
https://doi.org/10.1161/atvb.34.suppl_1.263
Autor:
Ali K Naji, Michael Wassler, George Britton, Harnath S Shelat, Yong-Jian Geng, David D McPherson, Melvin E Klegerman
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 33
Introduction. We have developed bifunctional echogenic liposomes (BF-ELIP) targeted to both CD34 and ICAM-1 to facilitate delivery of CD34+ stem cells to inflammatory endothelium. We previously confirmed that BF-ELIP enhanced CD34+ stem cell adherenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d686d3dd54921d27ac08dc9b7ef8983
https://doi.org/10.1161/atvb.33.suppl_1.a527
https://doi.org/10.1161/atvb.33.suppl_1.a527
Autor:
Melvin E Klegerman, Yuejiao Zou, George L Britton, Ali K Naji, Shao-Ling Huang, David D McPherson
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 32
Introduction. Bevacizumab (BEV) is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) that can ameliorate atheroma progression, the mechanism of which is believed to be through inhibition of neovascularization. Systemically,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::740227a48bc8b3366a3a4346fc0490bc
https://doi.org/10.1161/atvb.32.suppl_1.a342
https://doi.org/10.1161/atvb.32.suppl_1.a342